Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 32, 2002 - Issue 11
Submit an article Journal homepage
66
Views
12
CrossRef citations to date
0
Altmetric
Research Article

Disposition of LY333531, a selective protein kinase C β inhibitor, in the Fischer 344 rat and beagle dog

J. L. Burkey Lilly Research Laboratories, Division of Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285, USA
,
K. M. Campanale Lilly Research Laboratories, Division of Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285, USA
,
D. D. O'Bannon Lilly Research Laboratories, Division of Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285, USA
,
J. W. Cramer Lilly Research Laboratories, Division of Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285, USA
&
N. A. Farid Lilly Research Laboratories, Division of Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285, USA
Pages 1045-1052 | Published online: 22 Sep 2008

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

William G. Mayhan, Denise M. Arrick, Glenda M. Sharpe & Hong Sun. (2008) Age-Related Alterations in Reactivity of Cerebral Arterioles: Role of Oxidative Stress. Microcirculation 15:3, pages 225-236.
Read now
William G. Mayhan, Denise M. Arrick, Glenda M. Sharpe, Kaushik P. Patel & Hong Sun. (2006) Inhibition of NAD(P)H Oxidase Alleviates Impaired NOS-dependent Responses of Pial Arterioles in Type 1 Diabetes Mellitus. Microcirculation 13:7, pages 567-575.
Read now

Articles from other publishers (10)

William G. Mayhan & Denise M. Arrick. 2014. Diabetes: Oxidative Stress and Dietary Antioxidants. Diabetes: Oxidative Stress and Dietary Antioxidants 191 199 .
Denise M. Arrick & William G. Mayhan. 2014. Studies in Diabetes. Studies in Diabetes 13 36 .
Maciej J. Zamek-Gliszczynski, Trent L. Abraham, Jeffrey J. Alberts, Palaniappan Kulanthaivel, Kimberley A. Jackson, Kay H. Chow, Denis J. McCann, Haitao Hu, Shelby Anderson, Nathan A. Furr, Robert J. Barbuch & Kenneth C. Cassidy. (2013) Pharmacokinetics, Metabolism, and Excretion of the Glycogen Synthase Kinase-3 Inhibitor LY2090314 in Rats, Dogs, and Humans: A Case Study in Rapid Clearance by Extensive Metabolism with Low Circulating Metabolite Exposure. Drug Metabolism and Disposition 41:4, pages 714-726.
Crossref
Kapil Jain, Dara Ajay & M. Elizabeth Sobhia. (2011) Targeting PKC‐ β II and PKB Connection: Design of Dual Inhibitors . Molecular Informatics 30:4, pages 329-344.
Crossref
Prabhakara Reddy NagareddyHesham SolimanGuorong LinPadmesh S. RajputUjendra KumarJohn H. McNeillKathleen M. MacLeod. (2009) Selective Inhibition of Protein Kinase C β2 Attenuates Inducible Nitric Oxide Synthase–Mediated Cardiovascular Abnormalities in Streptozotocin-Induced Diabetic Rats. Diabetes 58:10, pages 2355-2364.
Crossref
Sishi Tang, Victor Xiao, Lianhu Wei, Catharine I. Whiteside & Lakshmi P. Kotra. (2008) Protein kinase C isozymes and their selectivity towards ruboxistaurin. Proteins: Structure, Function, and Bioinformatics 72:1, pages 447-460.
Crossref
David T. Kurtz. 2008. xPharm: The Comprehensive Pharmacology Reference. xPharm: The Comprehensive Pharmacology Reference 1 4 .
Jennifer L. Burkey, Kristina M. Campanale, Robert Barbuch, Douglas O'Bannon, James Rash, Charles Benson & David Small. (2006) Disposition of [ 14 C]Ruboxistaurin in Humans . Drug Metabolism and Disposition 34:11, pages 1909-1917.
Crossref
Robert J. Barbuch, Kristina Campanale, Chad E. Hadden, Milton Zmijewski, Ping Yi, Douglas D. O'Bannon, Jennifer L. Burkey & Palaniappan Kulanthaivel. (2006) IN VIVO METABOLISM OF [ 14 C]RUBOXISTAURIN IN DOGS, MICE, AND RATS FOLLOWING ORAL ADMINISTRATION AND THE STRUCTURE DETERMINATION OF ITS METABOLITES BY LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY AND NMR SPECTROSCOPY . Drug Metabolism and Disposition 34:2, pages 213-224.
Crossref
Scott V Joy, Ann C Scates, Srilaxmi Bearelly, Moahad Dar, Christina A Taulien, Jason A Goebel & Michael J Cooney. (2005) Ruboxistaurin, a Protein Kinase C β Inhibitor, as an Emerging Treatment for Diabetes Microvascular Complications. Annals of Pharmacotherapy 39:10, pages 1693-1699.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.